Natixis’s Rigel Pharmaceuticals RIGL Stock Holding History

Natixis’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-3,000	Closed	-$44.4K	–	1122
2024 Q1	$44.4K	Sell	3,000 -750	-20%	-$10.1K	﹤0.01%	830
2023 Q4	$54.4K	Hold	3,750	–	–	﹤0.01%	816
2023 Q3	$40.5K	Sell	3,750 -1,975	-34%	-$23.8K	﹤0.01%	838
2023 Q2	$73.8K	Buy	+5,725	New	+$77.4K	﹤0.01%	815

Other funds holding RIGL

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Natixis's RIGL Position: Q2 2024 in Review

Natixis sold out of Rigel Pharmaceuticals (RIGL) in Q2 2024, closing a stake of 3,000 shares — an estimated $44.4K sold.

Natixis first reported a position in RIGL in Q2 2023 and held it in 4 quarters. The position peaked at $73.8K in Q2 2023. 91 funds tracked by Wall St. Rank hold RIGL as of Q2 2024.

Natixis reported no remaining Rigel Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Natixis sold 3,000 Rigel Pharmaceuticals shares in Q2 2024, an estimated $44.4K.
Natixis first reported a position in Rigel Pharmaceuticals in Q2 2023 and held it in 4 quarters.
Natixis's Rigel Pharmaceuticals position peaked at $73.8K in Q2 2023.
91 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q2 2024.

Based on Natixis's 13F filing for Q2 2024, filed 13 Aug 2024.